Schwab Charles Investment Management Inc. raised its stake in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 5.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 770,778 shares of the medical instruments supplier’s stock after acquiring an additional 41,467 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.34% of DENTSPLY SIRONA worth $46,101,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Commonwealth Bank of Australia raised its stake in shares of DENTSPLY SIRONA by 19.0% during the 2nd quarter. Commonwealth Bank of Australia now owns 1,626 shares of the medical instruments supplier’s stock worth $104,000 after buying an additional 260 shares in the last quarter. Acrospire Investment Management LLC purchased a new position in shares of DENTSPLY SIRONA during the 2nd quarter worth approximately $113,000. Dupont Capital Management Corp purchased a new position in shares of DENTSPLY SIRONA during the 2nd quarter worth approximately $116,000. Massey Quick Simon & CO. LLC purchased a new position in shares of DENTSPLY SIRONA during the 3rd quarter worth approximately $124,000. Finally, Korea Investment CORP raised its stake in shares of DENTSPLY SIRONA by 139.9% during the 2nd quarter. Korea Investment CORP now owns 2,145 shares of the medical instruments supplier’s stock worth $139,000 after buying an additional 1,251 shares in the last quarter. 96.58% of the stock is owned by hedge funds and other institutional investors.
A number of equities research analysts recently weighed in on XRAY shares. UBS restated a “neutral” rating and issued a $59.00 price target (down previously from $62.00) on shares of DENTSPLY SIRONA in a report on Thursday, August 10th. Zacks Investment Research cut DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a report on Monday, October 30th. Jefferies Group lowered their target price on DENTSPLY SIRONA from $72.00 to $66.00 and set a “buy” rating on the stock in a report on Wednesday, August 23rd. Cleveland Research cut DENTSPLY SIRONA from a “buy” rating to a “neutral” rating in a report on Thursday, October 5th. Finally, BidaskClub cut DENTSPLY SIRONA from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 2nd. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $67.73.
In other news, insider Mark Thierer purchased 77,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The stock was acquired at an average cost of $66.04 per share, for a total transaction of $5,085,080.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Nicholas W. Alexos purchased 50,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The stock was purchased at an average price of $65.85 per share, with a total value of $3,292,500.00. The disclosure for this purchase can be found here. 1.99% of the stock is currently owned by company insiders.
Shares of DENTSPLY SIRONA Inc. (NASDAQ XRAY) opened at $65.50 on Thursday. DENTSPLY SIRONA Inc. has a 52-week low of $52.53 and a 52-week high of $68.98. The stock has a market capitalization of $15,069.50, a PE ratio of 26.14, a PEG ratio of 2.60 and a beta of 1.31. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.59 and a current ratio of 2.32.
DENTSPLY SIRONA (NASDAQ:XRAY) last announced its earnings results on Friday, November 3rd. The medical instruments supplier reported $0.70 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.66 by $0.04. DENTSPLY SIRONA had a positive return on equity of 7.56% and a negative net margin of 20.33%. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $978.99 million. During the same period in the previous year, the company earned $0.66 earnings per share. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. research analysts predict that DENTSPLY SIRONA Inc. will post 2.66 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Schwab Charles Investment Management Inc. Has $46.10 Million Holdings in DENTSPLY SIRONA Inc. (XRAY)” was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.thelincolnianonline.com/2017/12/07/schwab-charles-investment-management-inc-has-46-10-million-holdings-in-dentsply-sirona-inc-xray.html.
DENTSPLY SIRONA Company Profile
DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.
Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.